Chester County News and Community Website
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has announced the first patient was randomized in its BACKBEAT pivotal study in late December 2023. This marks a significant …
Orchestra BioMed’s Bioelectronic Therapy Pivotal Study Begins: A Potential Game-Changer for Hypertensive Patients Read More
PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has announced a clinical collaboration and supply agreement with Coherus BioSciences, Inc. (NASDAQ: CHRS) to evaluate the combination of INO-3112 and LOQTORZI™ (toripalimab-tpzi) …
INOVIO and Coherus BioSciences Join Forces for Phase 3 Clinical Trial in Throat Cancer Treatment Read More
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a leader in dermatology therapeutics, announced a significant development in its ongoing research for innovative skin cancer treatments. The company confirmed …
Verrica Pharmaceuticals Achieves Milestone in Phase 2 Trial of Groundbreaking Skin Cancer Therapy Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has announced that it received the minutes from its recent Type C meeting with the U.S. Food and Drug Administration (FDA). …
Verrica Pharmaceuticals Gains FDA Alignment for YCANTH’s Phase 3 Clinical Development Plan Read More
WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a Pennsylvania-based biotechnology company, has announced new preclinical data on two of its drug candidates, istaroxime and CVie-216. The drugs have shown …
Windtree’s Innovative Drugs Show Promising Reductions in Ventricular Arrhythmias Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company, recently announced that it has received alignment from the U.S. Food and Drug Administration (FDA) on the design of a …
Ocugen Gains FDA Alignment for Phase 3 Trial of Retinitis Pigmentosa Treatment Read More
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is making strategic moves, announcing several updates this week including promising trial results, a shift in drug development focus, and a significant …
Aclaris Therapeutics Advances ATI-1777 into Phase 2b Trial, Plans Workforce Reduction to Preserve Capital Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a leading dermatology therapeutics provider, has shared promising top-line results from the Phase 3 trial of TO-208 for molluscum contagiosum (“molluscum”) …
Verrica Pharmaceuticals Announces Positive Results from Phase 3 Trial of TO-208 for Molluscum Treatment in Japan Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company, recently made a significant stride in its quest for innovative vision restoration solutions. The company announced that the first patient …
Ocugen’s Pioneering Gene Therapy OCU410 Takes Major Step Forward in Clinical Trials Read More
BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS) has recently announced the completion of the last patient visit in its phase III study of buntanetap, a leading candidate for treating …
Annovis Bio Finalizes Phase III Study of Buntanetap in Early Parkinson’s Treatment, Awaits Topline Data Read More